Cigrovski Berkovic M, Giovanardi F, Mrzljak A, Lai Q. Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis. World J Diabetes 2023; 14(8): 1289-1300 [PMID: 37664473 DOI: 10.4239/wjd.v14.i8.1289]
Corresponding Author of This Article
Maja Cigrovski Berkovic, MD, PhD, Adjunct Associate Professor, Department of Kinesiological Anthropology and Methodology, Faculty of Kinesiology, University of Zagreb, Horvaćanski zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Meta-Analysis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Diabetes. Aug 15, 2023; 14(8): 1289-1300 Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1289
Prognostic role of metformin in diabetes mellitus type 2 patients with hepatocellular carcinoma: A systematic review and meta-analysis
Maja Cigrovski Berkovic, Francesco Giovanardi, Anna Mrzljak, Quirino Lai
Maja Cigrovski Berkovic, Department of Kinesiological Anthropology and Methodology, Faculty of Kinesiology, University of Zagreb, Zagreb 10000, Croatia
Francesco Giovanardi, Quirino Lai, General Surgery and Organ Transplantation Unit, Department of Surgery, Sapienza University of Rome, Rome 00018, Italy
Anna Mrzljak, Department of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb 10000, Croatia
Anna Mrzljak, Department of Medicine, School of Medicine, Zagreb 10000, Croatia
Author contributions: Lai Q and Mrzljak A contributed to the conception and design of the study; Giovanardi F and Lai Q contributed to the acquisition of data; Lai Q and Giovanardi F analyzed and interpreted the data; Mrzljak A and Cigovski Berkovic M drafted the article; Lai Q critically revised the manuscript; and all authors approved the final version.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Maja Cigrovski Berkovic, MD, PhD, Adjunct Associate Professor, Department of Kinesiological Anthropology and Methodology, Faculty of Kinesiology, University of Zagreb, Horvaćanski zavoj 15, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com
Received: February 27, 2023 Peer-review started: February 27, 2023 First decision: April 11, 2023 Revised: April 24, 2023 Accepted: May 16, 2023 Article in press: May 16, 2023 Published online: August 15, 2023 Processing time: 164 Days and 15.3 Hours
Core Tip
Core Tip: The identification of chemopreventive agents following hepatocellular carcinoma (HCC) treatments with the potential to lower the risk of its adverse course is of paramount relevance. Among them, metformin has been recently examined in this setting. The present systematic review and meta-analysis aim to determine the role of metformin in preventing HCC adverse events (i.e., death, tumor progression, and recurrence). Metformin only showed statistical significance as a protective factor for the risk of death in patients receiving curative therapies for HCC, but failed as a protective agent for progressive disease and recurrence. Further large studies are required to definitively clarify the real impact of metformin as a chemopreventive agent for HCC.
